GURU.Markets stock price, segment price, and overall market index valuation
The company's share price HilleVax Inc.
Shares of HilleVax, a biopharmaceutical company developing a norovirus vaccine, reflect the potential of this huge, yet untapped, market. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma virus
HilleVax is a biopharmaceutical company developing and commercializing a vaccine against norovirus, the leading cause of acute gastroenteritis. We classify it as "Viral Pharmaceuticals." The chart below shows the dynamics of this important public health segment.
Broad Market Index - GURU.Markets
HilleVax is a biotech company developing a vaccine to prevent norovirus, the leading cause of acute gastroenteritis. As a major player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with HilleVax's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
HLVX - Daily change in the company's share price HilleVax Inc.
For HilleVax, Inc., a vaccine developer, daily price change is a measure of the high volatility inherent in biotech. It reflects the market's reaction to clinical trial data and is a key parameter in the risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
HilleVax, Inc. is a biotech company specializing in vaccines. This chart highlights the sector's extreme volatility. Comparison with HLVX, whose success depends on vaccine approval and sales, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
HilleVax is a biotech company developing a vaccine against norovirus, a leading cause of gastrointestinal illness. Its shares move in sync with news about clinical trials. This high volatility is part of the market dynamics driven by hopes for new drugs.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization HilleVax Inc.
For HilleVax, Inc., the year-over-year trend is a story about developing a vaccine against norovirus, the leading cause of the "stomach flu." Its 12-month market cap depends entirely on progress in Phase III clinical trials. Success could make its vaccine the first of its kind and open a multibillion-dollar market.
Annual dynamics of market capitalization of the market segment - Pharma virus
HilleVax, Inc. is a late-stage biotech company developing a norovirus vaccine. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the potential for its drug to become a blockbuster and the associated risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
HilleVax is a clinical-stage biotech company whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its vaccine trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization HilleVax Inc.
HilleVax is developing a norovirus vaccine. As a clinical-stage company, its monthly performance is entirely dependent on the progress of trials. Positive data on the vaccine's efficacy and safety are fueling optimism, while any delays or setbacks could put significant pressure on the stock.
Monthly dynamics of market capitalization of the market segment - Pharma virus
HilleVax is a late-stage biotech company developing a vaccine to prevent norovirus, the leading cause of acute gastroenteritis. The chart below illustrates the overall dynamics of the biotech sector, where developing vaccines for common diseases has enormous commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
HilleVax is a biotech company developing a norovirus vaccine. Its value depends almost entirely on the success of this single project. Its shares will move based on news of clinical trials, and their performance will be completely unrelated to overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization HilleVax Inc.
The weekly performance of HilleVax, a company developing a norovirus vaccine, reflects the fight against common infections. Share prices are reacting to clinical trial data that could lead to the world's first vaccine against the "stomach flu."
Weekly dynamics of market capitalization of the market segment - Pharma virus
HilleVax is developing a vaccine to prevent norovirus. As a biotech company with a single key product, its value depends almost entirely on the success of this project. The chart will show whether HilleVax's share price performance reflects unique news about its vaccine or general investor sentiment in the viral pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
HilleVax is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help you understand: does HilleVax live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
HLVX - Market capitalization of the company HilleVax Inc.
HilleVax's market capitalization tells the story of a biotech company focused on developing a vaccine against norovirus, the leading cause of stomach flu. Its chart reflects progress in late-stage clinical trials. The trend reflects investors' assessment of the enormous commercial potential should the vaccine be successful and approved.
HLVX - Share of the company's market capitalization HilleVax Inc. within the market segment - Pharma virus
HilleVax is a biopharmaceutical company developing and commercializing vaccines, particularly against norovirus. Its market capitalization reflects the potential of its lead candidate in a huge market. This chart shows how investors assess its chances of developing the first successful vaccine against the "stomach flu."
Market capitalization of the market segment - Pharma virus
HilleVax is a biotech company developing a vaccine to prevent norovirus infection. The chart below shows the overall market capitalization of this sector. Its dynamics reflect the enormous need to prevent common infectious diseases, where a successful vaccine could become a blockbuster.
Market capitalization of all companies included in a broad market index - GURU.Markets
HilleVax is a biotech company developing a vaccine against norovirus, a leading cause of gastrointestinal illness. Its market cap reflects the hope that this widespread illness can be prevented. Its performance reflects how the market views the potential of vaccines against less lethal, but still highly prevalent, diseases.
Book value capitalization of the company, segment and market as a whole
HLVX - Book value capitalization of the company HilleVax Inc.
HilleVax's foundation is its capital, invested in the late-stage development of a vaccine against norovirus, a leading cause of gastrointestinal illness. This is a tangible, scientific foundation for solving a major public health problem. How has this biotech asset evolved? The chart below shows its dynamics.
HLVX - Share of the company's book capitalization HilleVax Inc. within the market segment - Pharma virus
HilleVax is developing a norovirus vaccine, which requires R&D labs and manufacturing partnerships. The chart shows the proportion of its tangible assets, reflecting the physical foundation of its efforts to combat the widespread disease.
Market segment balance sheet capitalization - Pharma virus
HilleVax develops vaccines, specifically against norovirus. This is a knowledge-intensive process, where R&D and patents are its main assets. The book value chart shows how "light" the company's material base is, while the main value is created in the labs.
Book value of all companies included in the broad market index - GURU.Markets
HilleVax, Inc. is developing a vaccine against norovirus. Its book value represents its capital for large-scale clinical trials and manufacturing contracts. The chart shows the material foundation that forms the basis for creating the world's first vaccine against this widespread infection.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - HilleVax Inc.
HilleVax's balance sheet is capital. But the market sees a potential norovirus vaccine. The chart shows a huge "hope factor": the premium investors are paying for the potential of its drug to become first-in-class and generate billions.
Market to book capitalization ratio in a market segment - Pharma virus
HilleVax is a biotech company developing a norovirus vaccine. Its value depends almost entirely on the success of this single program. The chart shows the enormous bet investors are making on the vaccine's commercial success.
Market to book capitalization ratio for the market as a whole
HilleVax is a biotech company developing a vaccine against norovirus, a leading cause of gastrointestinal infections worldwide. The development of such a vaccine would be a major breakthrough. This chart shows the overall market valuation, but how do investors value this potential blockbuster that could prevent millions of cases annually?
Debts of the company, segment and market as a whole
HLVX - Company debts HilleVax Inc.
HilleVax, a biotech company, is in late-stage vaccine development. This chart illustrates the enormous financial resources required to conduct large-scale Phase III clinical trials for its norovirus candidate. This is the final and most expensive stage before potential market entry.
Market segment debts - Pharma virus
HilleVax is a biotech company developing a vaccine against norovirus, the leading cause of gastroenteritis. Developing a successful vaccine is extremely expensive and carries significant risk. This chart shows how the company is raising capital to conduct large-scale clinical trials of its vaccine candidate.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio HilleVax Inc.
HilleVax is a biotech company developing vaccines, particularly against norovirus. This chart shows how reliant it is on debt to conduct large-scale and expensive Phase III clinical trials. Debt here represents an investment in a potential blockbuster drug that could prevent a widespread disease.
Market segment debt to market segment book capitalization - Pharma virus
HilleVax is a biopharmaceutical company developing a norovirus vaccine. This chart shows the overall debt burden in the vaccine development sector. It helps understand how companies finance their large and expensive Phase III clinical trials, and how HilleVax, focused on a single product, manages its finances.
Debt to book value of all companies in the market
HilleVax is a biotech company developing a norovirus vaccine. Currently in clinical trials, it is entirely dependent on equity capital. The market's total debt load chart doesn't reflect its specifics, as its future is determined by research success and regulatory approval, not leverage management.
P/E of the company, segment and market as a whole
P/E - HilleVax Inc.
This chart for HilleVax, a company developing a norovirus vaccine, shows its potential blockbuster valuation. The multiple reflects investors' belief in the huge market for an effective vaccine against this widespread disease. This is a bet on success in late-stage clinical trials and future commercialization.
P/E of the market segment - Pharma virus
Vaccine development, the focus of HilleVax, is a high-potential field. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that HilleVax, which is focused on a norovirus vaccine, is valued based on the huge potential market for this disease, for which there is currently no treatment.
P/E of the market as a whole
HilleVax, Inc. is a clinical-stage biopharmaceutical company developing a vaccine to prevent norovirus, the leading cause of acute gastroenteritis. It is a disease with a significant global burden. This biotech sentiment chart helps understand how the market views the potential of vaccines to prevent common infectious diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company HilleVax Inc.
HilleVax is a biotech company developing a vaccine against norovirus, the leading cause of acute gastroenteritis. This chart reflects investor expectations for the success of its clinical trials. The trendline estimates the commercial potential of this first-of-its-kind vaccine against this common disease.
%20P%2FE%20HilleVax%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-HilleVax-Inc.&v=1772513802141 "Chart of the company's future (projected) P/E HilleVax Inc.")
Future (projected) P/E of the market segment - Pharma virus
HilleVax is a biotech company developing a vaccine against norovirus, the leading cause of acute gastroenteritis. This chart shows profitability expectations for the sector, helping to understand how highly the market values the potential of its vaccine candidate to address a significant public health problem.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772513802154 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
HilleVax, Inc. is a clinical-stage biopharmaceutical company developing and commercializing vaccines against norovirus. This chart shows investor risk appetite. For a company focused on preventing a widespread disease for which there is currently no vaccine, it reflects the market's willingness to fund important preventative developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513802171 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit HilleVax Inc.
HilleVax, Inc. is a clinical-stage biotechnology company focused on developing a norovirus vaccine. The financial outcome illustrated in this chart is based on the costs of conducting large-scale clinical trials. It shows the cost of developing a first-of-its-kind vaccine to prevent this common gastrointestinal disease.
Profit of companies in the market segment - Pharma virus
HilleVax is a biotechnology company developing and commercializing vaccines, primarily against norovirus, the leading cause of acute gastroenteritis. The company's success hinges on the results of clinical trials. This chart illustrates how developing vaccines for common diseases can fill a huge need and generate significant profits.
Overall market profit
HilleVax is a biotech company developing a vaccine against norovirus, a leading cause of gastroenteritis. Its success depends entirely on the results of clinical trials and subsequent commercialization. It is an example of a company solving a significant public health problem that requires significant capital, which is readily available in a strong economic environment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company HilleVax Inc.
HilleVax is a biopharmaceutical company developing a vaccine against norovirus. The profit/loss forecast in this chart reflects analysts' expectations for the success of clinical trials and the huge potential market for a first-of-its-kind vaccine against this widespread disease.
%20profit%20of%20the%20company%20HilleVax%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-HilleVax-Inc.&v=1772513802220 "Graph of future (projected) profit of the company HilleVax Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
HilleVax, Inc. is a biopharmaceutical company focused on the development and commercialization of vaccines against norovirus, the leading cause of acute gastroenteritis. This chart shows revenue projections for the viral pharmaceuticals sector, highlighting the huge potential market for the first-of-its-kind vaccine being developed by HilleVax.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772513802227 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
HilleVax is a biopharmaceutical company developing a norovirus vaccine. Its success depends on the results of clinical trials and subsequent commercialization. This schedule, reflecting market sentiment, affects the availability of capital needed to conduct large-scale research and bring the vaccine to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513802229 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - HilleVax Inc.
HilleVax is a biotech company developing a vaccine to prevent norovirus, the leading cause of acute gastroenteritis. This chart shows investor expectations for its lead candidate. The valuation is a bet that its vaccine will address a major public health problem.
P/S market segment - Pharma virus
HilleVax is a biotech company in late-stage clinical development focused on developing a vaccine against norovirus, the leading cause of acute gastroenteritis. This chart shows the industry average market capitalization to revenue ratio. It reflects investor expectations for the potential success of the vaccine, which could have a huge market.
P/S of the market as a whole
HilleVax is a clinical-stage biopharmaceutical company developing and commercializing vaccines against norovirus, the leading cause of acute gastroenteritis. This chart helps understand how the market values companies focused on developing vaccines for common but currently unpreventable diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company HilleVax Inc.
HilleVax is a biotech company developing a vaccine to prevent norovirus, the leading cause of acute gastroenteritis. This chart shows its valuation relative to projected future sales. It reflects investor expectations for the success of its clinical trials and the enormous market potential of such a vaccine.
%20P%2FS%20HilleVax%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-HilleVax-Inc.&v=1772513802302 "The graph of the company's future (projected) P/S HilleVax Inc.")
Future (projected) P/S of the market segment - Pharma virus
HilleVax is a clinical-stage biopharmaceutical company developing and commercializing vaccines against norovirus, the leading cause of acute gastroenteritis. This chart reflects investor expectations for its lead vaccine candidate and its potential in the vast infectious disease prevention market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772513802306 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
HilleVax is a biotech company developing a norovirus vaccine. Its future depends entirely on the success of clinical trials and regulatory approval. This general expectations chart for HLVX is not a direct driver. Demand for an effective vaccine will be determined by healthcare needs, not the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513802326 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales HilleVax Inc.
This chart illustrates the financial trajectory of a biotech company. For HilleVax, which is focused on developing a norovirus vaccine, it reflects funding from investors to finance late-stage clinical trials, not commercial sales revenue.
Sales of companies in the market segment - Pharma virus
HilleVax, Inc. is a clinical-stage biopharmaceutical company developing a vaccine against norovirus, the leading cause of acute gastroenteritis. A vaccine does not yet exist. This chart shows revenue in the pharmaceutical sector. HilleVax's success could prevent millions of cases and create a huge new vaccine market.
Overall market sales
HilleVax is a biotechnology company developing a vaccine against norovirus, the leading cause of viral gastroenteritis. A successful vaccine could have significant public health implications. The company exemplifies how pharmaceutical innovations are solving common medical problems while creating new markets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company HilleVax Inc.
HilleVax is developing a vaccine to prevent norovirus, the leading cause of acute gastroenteritis. Future sales projections depend on the success of its clinical trials and potential entry into the large market.
%20sales%20of%20the%20company%20HilleVax%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-HilleVax-Inc.&v=1772513802382 "Schedule of future (projected) sales of the company HilleVax Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
HilleVax, Inc. is a biopharmaceutical company developing a vaccine against norovirus. The forecast for the antiviral pharmaceutical sector shows a high unmet demand for the prevention of common illnesses. The chart illustrates the potential market for a first-in-class vaccine against the "stomach flu."
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772513802384 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
HilleVax is a biotech company developing a vaccine to prevent norovirus. Its success depends entirely on the results of clinical trials and subsequent regulatory approval. The overall economic situation, reflected in this chart, does not affect the demand for such a vaccine, but it may influence future government vaccination programs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513802388 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality HilleVax Inc.
HilleVax is a biotech company in late-stage development of a norovirus vaccine. Its financial performance reflects the enormous costs of conducting Phase III clinical trials. This chart illustrates the "cost of innovation"—the investment required to bring a potentially highly sought-after vaccine to market.
Market segment marginality - Pharma virus
HilleVax is a clinical-stage biotechnology company focused on the development and commercialization of norovirus vaccines. Profitability is contingent on successful completion of trials and regulatory approval. This metric reflects the company's operational structure as it works to address a serious public health problem.
Market marginality as a whole
HilleVax, Inc. is a clinical-stage biotech company developing a norovirus vaccine. This chart represents average profitability. Compared to this, HilleVax is a classic biotech. The company is not profitable and is investing in clinical trials. Its future profitability is entirely dependent on the success and commercialization of this single vaccine.
Employees in the company, segment and market as a whole
Number of employees in the company HilleVax Inc.
HilleVax is a biotech company in the late-stage development of a vaccine for the prevention of norovirus. Its team growth, which can be seen in this chart, is directly related to the preparation and execution of large-scale Phase III clinical trials. This staff expansion is a key step toward potential approval and launch of the vaccine.
Share of the company's employees HilleVax Inc. within the market segment - Pharma virus
HilleVax is a late-stage biopharmaceutical company focused on developing a vaccine against norovirus, the leading cause of acute gastroenteritis. This chart illustrates its scientific focus. It reflects the percentage of virologists and clinical vaccine researchers working on this important public health issue that HilleVax attracts.
Number of employees in the market segment - Pharma virus
HilleVax is developing a vaccine to prevent norovirus, a leading cause of gastroenteritis. This graph illustrates its work in vaccinology. The growth of the clinical team here signifies progress in solving an important public health problem, as the development of an effective vaccine could prevent millions of cases worldwide.
Number of employees in the market as a whole
HilleVax, Inc. is a biotechnology company developing a norovirus vaccine. Their activities are entirely focused on clinical trials. This general work schedule is irrelevant to them. Success in research and regulatory approval are the only things that matter to their future and ability to commercialize the product.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company HilleVax Inc. (HLVX)
HilleVax is a biotech company developing a vaccine against norovirus, the leading cause of acute gastroenteritis. This chart shows how the market views the vaccine's potential. The high market capitalization per employee reflects the huge potential market for such a vaccine and investors' confidence in the success of clinical trials.
%20of%20the%20company%20HilleVax%20Inc.%20(HLVX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-HilleVax-Inc.-HLVX&v=1772513802509 "Chart of market capitalization per employee (in thousands of dollars) of the company HilleVax Inc. (HLVX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
HilleVax is developing a norovirus vaccine. Like many biotech companies working on a single key product, the company's market cap reflects the potential market size for the vaccine. This chart shows the enormous value investors are placing on the success of clinical trials conducted by a relatively small scientific team.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772513802532 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
HilleVax is a biopharmaceutical company developing a norovirus vaccine. This graph reflects the employee's high valuation, as a successful vaccine against this common disease could become a blockbuster and generate billions in revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513802548 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company HilleVax Inc. (HLVX)
HilleVax is a biotech company in the late stages of developing a vaccine for norovirus (the so-called "stomach flu"). This is their only major asset—the R&D company. This metric is negative. It reflects how much capital the company is burning per employee to conduct large-scale Phase 3 clinical trials and bring this potentially popular vaccine to market.
%20Chart%20HilleVax%20Inc.%20(HLVX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-HilleVax-Inc.-HLVX&v=1772513802575 "Company Profit Per Employee (in thousands of dollars) Chart HilleVax Inc. (HLVX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
HilleVax (HLVX) is a biotech company developing a vaccine (against norovirus). Like other R&D companies, this chart shows a future target. Currently, profitability is negative. HLVX's success will depend on the approval of their vaccine, which would allow the small team to monetize a huge potential market and significantly exceed the industry benchmark.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772513802581 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
HilleVax (HLVX) is a biotech company developing vaccines, particularly against norovirus. Vaccine development is a lengthy and expensive process. The company is in the clinical stage. Negative profit per employee is the norm. The chart shows the "cost" of the scientific team conducting trials of a potential blockbuster vaccine.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513802585 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee HilleVax Inc. (HLVX)
HilleVax is a biotech company developing vaccines, specifically against norovirus. This chart reflects its clinical-stage status. Lack of revenue is normal. This metric demonstrates potential: a successful vaccine can generate enormous global revenue with a relatively small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-HilleVax-Inc.-HLVX&v=1772513802599 "Sales chart per company employee HilleVax Inc. (HLVX)")
Sales per employee in the market segment - Pharma virus
HilleVax is a late-stage biotech company developing a vaccine against norovirus (the so-called stomach flu). During the R&D phase, this metric reflects how effectively their scientific and clinical teams generate revenue (e.g., from partnerships) while advancing their potential blockbuster vaccine toward commercialization.
Sales per employee for the market as a whole
HilleVax is a clinical-stage biotech company focused on developing a vaccine against norovirus (the main cause of the "stomach flu"). It's an R&D company. This chart shows revenue per employee, which, as expected, is zero. It emphasizes that the company doesn't sell products but rather invests in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company HilleVax Inc. (HLVX)
HilleVax is a biotech company developing a vaccine against norovirus (stomach flu). This represents a huge potential market. This chart shows bearish bets. Bears are betting that the development of a vaccine against this complex virus will fail in clinical trials, which is a binary risk for the company.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-HilleVax-Inc.-HLVX&v=1772513802644 "Short Shares Chart for the Company HilleVax Inc. (HLVX)")
Shares shorted by market segment - Pharma virus
HilleVax is a biotech company developing a vaccine for norovirus (the so-called "stomach flu"). This chart shows overall short positions in the biotech sector. If it's high, it reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (like the FDA) across the sector.
Shares shorted by the overall market
HilleVax (HLVX) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing that HLVX will be unable to raise funds for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator HilleVax Inc. (HLVX)
HilleVax is a biotech "single bet." Their entire value is tied to the success of their sole candidate—a vaccine against norovirus ("stomach flu"). This chart measures the extremes of speculative expectations. It shows when the stock is "overbought" on data euphoria or "oversold" to the bottom.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-HilleVax-Inc.-HLVX&v=1772513802705 "RSI 14 indicator chart for the company's stock HilleVax Inc. (HLVX)")
RSI 14 Market Segment - Pharma virus
HilleVax (HLVX) is a biotech company, a "norovirus" (stomach flu) hunter. Their *only* bet is a *vaccine* (HIL-214). The "Pharma virus" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is HLVX's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
HilleVax (HLVX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HLVX (HilleVax Inc.)
HilleVax is a biotech company developing a vaccine (HIL-214) for the prevention of norovirus, a highly contagious "stomach flu." This chart shows the average target price. Analysts' estimates are based on clinical data and the enormous market potential of the first approved norovirus vaccine.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HLVX-HilleVax-Inc.&v=1772513802728 "A chart showing analyst consensus forecasts for the expected stock price. HLVX (HilleVax Inc.)")
The difference between the consensus estimate and the actual stock price HLVX (HilleVax Inc.)
HilleVax is a biotech company whose sole goal is to commercialize a vaccine for norovirus (the "stomach flu"). It's a huge, yet untapped, market. This chart shows how far the current share price differs from the "fair" value predicted by analysts. It reflects their faith in the success of this single, yet crucial, R&D project.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HLVX-HilleVax-Inc.&v=1772513802730 "A chart showing the difference between the consensus forecast and the actual stock price. HLVX (HilleVax Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
HilleVax is a biotech company focused on one goal: bringing to market a vaccine against norovirus (the "stomach flu"), a global health problem. This chart displays the overall expectations of pharmaceutical analysts, demonstrating whether experts believe this single-product R&D bet will be successful.
Analysts' consensus forecast for the overall market share price
HilleVax (HLVX) is a biopharmaceutical company aiming to defeat the stomach flu. They are developing a vaccine against norovirus, one of the most contagious diseases in the world. This chart shows the overall risk appetite, reflecting the willingness of investors to fund vaccine R&D projects, which require massive investment.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index HilleVax Inc.
HilleVax is a biotech company with one bet: a norovirus vaccine (HIL-214). Norovirus is a stomach flu that causes millions of illnesses but for which there is still no vaccine. It's a huge market. This chart is purely an indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of success.
AKIMA Market Segment Index - Pharma virus
HilleVax is a biotech company developing a vaccine (HIL-214) for the prevention of norovirus, the leading cause of acute gastroenteritis. This chart shows the average index for the antiviral drug sector. It helps investors assess how HilleVax's performance compares to the industry average.
The AKIM Index for the overall market
HilleVax is a biopharmaceutical company focused exclusively on developing a norovirus vaccine. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing this company's prospects following clinical setbacks and the need to preserve capital.
